Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Multiple Sclerosis

Free Subscription Articles published in Eur Neurol Retrieve available abstracts of 25 articles: HTML format Text format

Single Articles

October 2017
1. LECAT M, Decavel P, Magnin E, Lucas B, et al
   Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review.
   Eur Neurol. 2017;78.
   PubMed     Text format     Abstract available
   
   
   July 2017
2. GRASSO MG, Broccoli M, Casillo P, Catani S, et al
   Evaluation of the Impact of Cognitive Training on Quality of Life in Patients with Multiple Sclerosis.
   Eur Neurol. 2017;78.
   PubMed     Text format     Abstract available
   
   
   
3. GONZALES B, Chopard G, Charry B, Berger E, et al
   Effects of a Training Program Involving Body Cooling on Physical and Cognitive Capacities and Quality of Life in Multiple Sclerosis Patients: A Pilot Study.
   Eur Neurol. 2017;78.
   PubMed     Text format     Abstract available
   
   
   May 2017
4. KAUV P, Ayache SS, Creange A, Chalah MA, et al
   Adenosine Triphosphate Metabolism Measured by Phosphorus Magnetic Resonance Spectroscopy: A Potential Biomarker for Multiple Sclerosis Severity.
   Eur Neurol. 2017;77.
   PubMed     Text format     Abstract available
   
   
   April 2017
5. HABEK M, Krbot Skoric M, Crnosija L, Gabelic T, et al
   Postural Orthostatic Tachycardia Predicts Early Conversion to Multiple Sclerosis after Clinically Isolated Syndrome.
   Eur Neurol. 2017;77.
   PubMed     Text format     Abstract available
   
   
   March 2017
6. SAHRAIAN MA, Rezaali S, Hosseiny M, Doosti R, et al
   Sleep Disorder as a Triggering Factor for Relapse in Multiple Sclerosis.
   Eur Neurol. 2017;77.
   PubMed     Text format     Abstract available
   
   
   
7. BURGGRAAFF J, Knol DL, Uitdehaag BM
   Regression-Based Norms for the Symbol Digit Modalities Test in the Dutch Population: Improving Detection of Cognitive Impairment in Multiple Sclerosis?
   Eur Neurol. 2017;77.
   PubMed     Text format     Abstract available
   
   
   January 2017
8. VILLAVERDE-GONZALEZ R, Gracia Gil J, Perez Sempere A, Millan Pascual J, et al
   Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.
   Eur Neurol. 2017;77.
   PubMed     Text format     Abstract available
   
   
   December 2016
9. MOREAU T, Bungener C, Heinzlef O, Suchet L, et al
   Anxiety and Coping Strategy Changes in Multiple Sclerosis Patients Initiating Fingolimod: The GRACE Prospective Study.
   Eur Neurol. 2016;77.
   PubMed     Text format     Abstract available
   
   
   October 2016
10. VERMERSCH P, Trojano M
    Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Eur Neurol. 2016;76.
    PubMed     Text format     Abstract available
    
    
    
11. VILLAR-QUILES RN, Matias-Guiu JA, Ortega G, Gonzalez-Suarez I, et al
    Analysis of the Relationship between the Month of Birth and Risk of Multiple Sclerosis in a Spanish Population.
    Eur Neurol. 2016;76.
    PubMed     Text format     Abstract available
    
    
    August 2016
12. NOVOTNA K, Sobisek L, Horakova D, Havrdova E, et al
    Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5).
    Eur Neurol. 2016;76.
    PubMed     Text format     Abstract available
    
    
    July 2016
13. CARDAIOLI G, Di Filippo M, Bianchi A, Eusebi P, et al
    Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency.
    Eur Neurol. 2016;76.
    PubMed     Text format     Abstract available
    
    
    
14. MECA-LALLANA J, Hernandez L, Caminero AB, Giron JM, et al
    Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-beta to Glatiramer Acetate in Clinical Practice.
    Eur Neurol. 2016;76.
    PubMed     Text format     Abstract available
    
    
    June 2016
15. SCHIMRIGK S, Faiss J, Kohler W, Gunther A, et al
    Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption - Observational Multicenter Study with 147 Patients.
    Eur Neurol. 2016;75.
    PubMed     Text format     Abstract available
    
    
    
16. RIBES GARCIA S, Gomez-Pajares F, Albelda Puig C, Garcia Herrera JL, et al
    Description of the Characteristics of Multiple Sclerosis Patients in the Region of Valencia (Spain) Who Requested Treatment with Disease-Modifying Drugs during the 2005-2014 Decade.
    Eur Neurol. 2016;75.
    PubMed     Text format     Abstract available
    
    
    May 2016
17. HAUPTS M, Vila C, Jonas A, Witte K, et al
    Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Eur Neurol. 2016;75.
    PubMed     Text format     Abstract available
    
    
    April 2016
18. TANAKA M, Nakahara K, Kinoshita M
    Increased Signal Intensity in the Dentate Nucleus of Patients with Multiple Sclerosis in Comparison with Neuromyelitis Optica Spectrum Disorder after Multiple Doses of Gadolinium Contrast.
    Eur Neurol. 2016;75.
    PubMed     Text format     Abstract available
    
    
    January 2016
19. GIANTZI V, Karapanayiotides T, Lagoudaki R, Poulatsidou KN, et al
    The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies.
    Eur Neurol. 2016;75.
    PubMed     Text format     Abstract available
    
    
    
20. PATTI F
    Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Eur Neurol. 2016;75 Suppl 1:9-12.
    PubMed     Text format     Abstract available
    
    
    
21. TROJANO M
    THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Eur Neurol. 2016;75 Suppl 1:4-8.
    PubMed     Text format     Abstract available
    
    
    
22. FERNANDEZ O
    THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Eur Neurol. 2016;75 Suppl 1:1-3.
    PubMed     Text format     Abstract available
    
    
    December 2015
23. ALTINTAS A, Najar B, Gozubatik-Celik G, Menku SF, et al
    Pregnancy Data in a Turkish Multiple Sclerosis Population.
    Eur Neurol. 2015;74.
    PubMed     Text format     Abstract available
    
    
    
24. MAGNIN E, Sagawa Y Jr, Chamard L, Berger E, et al
    Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis.
    Eur Neurol. 2015;74.
    PubMed     Text format     Abstract available
    
    
    November 2015
25. TROJANO M, Vila C
    Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Eur Neurol. 2015;74.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: